Industrials · Industrial Instruments For Measurement, Display, and Control

MLAB MESA LABORATORIES INC /CO/ SEC Filings & Insider Trading Activity 2026

company
CIK 724004115 filings
Russell 2000

MLAB at a glance

MESA LABORATORIES INC /CO/ (MLAB, SEC CIK 724004) filed its latest 10-K annual report on June 3, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended March 31, 2026 (FY2026), MESA LABORATORIES INC /CO/ (MLAB) reported revenue of $249.1 million (up 3.4% from FY2025) and net income of $6.7 million. Diluted EPS was $1.21.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding MESA LABORATORIES INC /CO/ (MLAB) shares worth $266.0 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$249.1M
+3.4% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$266.0M · +0 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material risk-factor changes during quarter, per filing
  • Carried-forward risks remain those disclosed in March 31, 2026 Form 10-K
  • Credit agreement amended September 16, 2026, indicating potential financing-risk developments
  • New share repurchase program approved November 4, 2026, after quarter-end, affecting capital-allocation risk

AI summary of the MLAB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Mesa Laboratories’ fiscal Q2 and first-half results through September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, earnings, margins, guidance and segment performance details

Item EX-99.1: Item EX-99.1

  • 2Q27 revenue $62.3M, up 2.6%; adjusted EBITDA $17.3M, margin 27.8% versus 23.5%, signaling substantial operating leverage
  • SDC revenue rose 14.6% to $25.3M, while BPD and Clinical Genomics declined 8.2% and 8.8%, respectively
Filed Oct 13, 2026Full analysis →

Item 2.05: Costs Associated with Exit or Disposal Activities

  • Approximately 40 positions eliminated, primarily in Clinical Genomics, signaling a narrower focus on pharmacogenomics, oncology and high-utilization accounts
  • Hamburg, Germany facility exit targeted for February 2027 lease expiration

Item 7.01: Regulation FD Disclosure

  • Press release announces Mesa Laboratories’ Restructuring Program
  • Exhibit 99.1 contains the program details, including expected scope and financial impact
Filed Sep 8, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Annual meeting quorum: 4,872,692 of 5,595,869 eligible shares represented
  • All seven director nominees reelected to one-year terms through 2027 annual meeting

AI summaries of MLAB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MLAB

Don't miss the next MLAB filing

  • Alerts as it files. A push when MLAB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MLAB, by share count.
  • Ask anything. An AI agent that reads every MLAB filing and answers with sources.

MLAB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Sullivan John JamesGOct 13, 2026-
Ladiwala Shiraz ShabanaliASep 9, 2026-
Hall ShannonASep 9, 2026-
Sullivan John JamesASep 9, 2026-
Capone Mark ChristopherASep 9, 2026-
Tripeny R TonyASep 9, 2026-
Tripeny R TonyMAug 15, 2026-
Sullivan John JamesMAug 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$241.0M$249.1M
Gross Profit-$150.9M$158.3M
Operating Income-$16.3M$18.5M
Net Income--$2.0M$6.7M
Gross Margin-62.6%63.5%
Op. Margin-6.8%7.4%
Net Margin--0.8%2.7%
Balance Sheet
Total Assets$446.8M$433.3M$427.7M
Equity$145.4M$159.8M$186.2M
ROE--1.2%3.6%
Per Share
EPS-$-0.36$1.21
Cash Flow
Operating CF-$46.8M$42.8M
CapEx-$4.2M$3.3M

Source: XBRL data in MESA LABORATORIES INC /CO/ (MLAB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MLAB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MLAB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$266.0M
Q2 202627$208.4M
Q1 202627$158.8M
Q4 202525$135.2M
Q3 202527$119.2M
Q2 202528$234.6M
Q1 202524$203.9M
Q4 202421$184.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MLAB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Oct 29, 2026--
8-KOct 13, 2026Analysis-
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
8-KSep 8, 2026Analysis-
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
8-KAug 10, 2026Analysis-
10-QAug 10, 2026Analysis
8-KJul 30, 2026Analysis-
4Jun 23, 2026--
4Jun 23, 2026--

Related Industrials companies

All Industrials →

MLAB SEC filings: frequently asked questions

Which institutions hold MLAB stock?

As of September 30, 2026, the largest MESA LABORATORIES INC /CO/ (MLAB) holders among the 13F filers tracked by SignalX were BlackRock ($59.5 million), Vanguard Capital Management LLC ($30.7 million), Raymond James Financial ($22.8 million), Dimensional Fund Advisors ($21.3 million), Morgan Stanley ($18.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MLAB's revenue in fiscal year 2026?

For the fiscal year ended March 31, 2026 (FY2026), MESA LABORATORIES INC /CO/ (MLAB) reported revenue of $249.1 million (up 3.4% from FY2025) and net income of $6.7 million. Diluted EPS was $1.21. The figures come from the XBRL data in the 10-K.

What did MLAB report in its latest 8-K?

MESA LABORATORIES INC /CO/ (MLAB) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Mesa Laboratories’ fiscal Q2 and first-half results through September 30, 2026.

What are the latest MLAB SEC filings?

MESA LABORATORIES INC /CO/ (MLAB) filed its latest 10-K annual report on June 3, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 29, 2026.

What is MLAB's SEC CIK number?

MESA LABORATORIES INC /CO/ (MLAB)'s SEC Central Index Key (CIK) is 724004. EDGAR lists every MLAB filing under that number.

Ask anything about MLAB

The research agent reads MLAB's filings, financials, insider trades and 13F holders, then answers with sources.